Goldman Sachs Upgrades Cepheid (CPHD) to Buy
Tweet
Share
E-mailGet Alerts CPHD Hot Sheet
Price: $52.95 --0%
Rating Summary:
11 Buy, 14 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Rating Summary:
11 Buy, 14 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Join SI Premium – FREE
Goldman Sachs upgraded Cepheid (NASDAQ: CPHD) from Neutral to Buy with a price target of $45 (up from $36).
The firm noted Q2 results were impressive, new products were announced at AACC, menu expansion remains strong and the scarcity value of growth is
increasing.
Goldman is modeling a 3-year forward revenue CAGR of 21%, which could see more upside if small hospital penetration improves and TB testing expands.
For more ratings news on Cepheid click here and for the rating history of Cepheid click here.
Shares of Cepheid closed at $35.68 yesterday.
The firm noted Q2 results were impressive, new products were announced at AACC, menu expansion remains strong and the scarcity value of growth is
increasing.
Goldman is modeling a 3-year forward revenue CAGR of 21%, which could see more upside if small hospital penetration improves and TB testing expands.
For more ratings news on Cepheid click here and for the rating history of Cepheid click here.
Shares of Cepheid closed at $35.68 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Upgrades Tesla (TSLA) to Buy on wind up of positive catalysts
- Wells Fargo Upgrades Neurocrine Bio. (NBIX) to Overweight 'as the Company is Knocking on the Doors of the Large-Cap Club'
- Huber Research Upgrades Criteo S.A. (CRTO) to Overweight
Create E-mail Alert Related Categories
Hot Upgrades, UpgradesRelated Entities
Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
